MedTrace Logo

Efficacy and Safety Study of Tripterygium Glycoside in the Treatment of Crohn's Disease for Induction Remission

NCT02044952 · Status: UNKNOWN · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2014-01-24

No results posted yet for this study

Summary

The purpose of this study is to assess the effect and safety of Tripterygium Glycosides in the treatment of Crohn's disease for induction remission and compare the therapeutic effect with patients who received mesalazine.

Conditions

  • Inflammatory Bowel Diseases
  • Crohn's Disease
  • Gastrointestinal Diseases
  • Digestive System Diseases
  • Intestinal Diseases

Interventions

DRUG

Mesalazine, Tripterygium glycosides

tripterygium glycosides: 2mg/kg/d, oral Mesalazine: 4g/d, oral

Sponsors & Collaborators

  • Zhu Weiming

    lead OTHER

Principal Investigators

  • wei ming zhu, PhD,MD · General Surgery Institute, Jinling Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
SINGLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-01-31
Primary Completion
2016-05-31
Completion
2016-07-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02044952 on ClinicalTrials.gov